CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 546 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdc7-IN-18
CAS:Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).Fórmula:C19H21N5OSForma y color:SolidPeso molecular:367.47Protein kinase inhibitor 11
CAS:Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.Fórmula:C21H18FN5O2SForma y color:SolidPeso molecular:423.463CTX-712
CAS:CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.Fórmula:C19H17FN8O2Forma y color:SolidPeso molecular:408.39CDK9-IN-38
CAS:CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.Fórmula:C22H23N5O3SForma y color:SolidPeso molecular:437.515Cdc7-IN-19
CAS:Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].Fórmula:C19H21N5O2Forma y color:SolidPeso molecular:351.40PKMYT1-IN-7
CAS:PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.Fórmula:C17H18FN5O3Forma y color:SolidPeso molecular:359.355CDK4-IN-1
CAS:CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50Fórmula:C22H29ClN8Pureza:98%Forma y color:SolidPeso molecular:440.97P162-0948
CAS:P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.Fórmula:C20H15FN4O2Forma y color:SolidPeso molecular:362.357CDK4/9-IN-1
CAS:CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.Fórmula:C22H34N6O2Forma y color:SolidPeso molecular:414.544CDK2-IN-39
CAS:CDK2-IN-39 (compound 4) is a CDK2 inhibitor.Fórmula:C14H15N3O4SForma y color:SolidPeso molecular:321.352CDK2-IN-40
CAS:CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.Fórmula:C16H21N7O2Forma y color:SolidPeso molecular:343.384Zeltociclib
CAS:Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.Fórmula:C18H20F3N4O2PForma y color:SolidPeso molecular:412.346CDK4/6-IN-24
CAS:CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.Fórmula:C32H41N7O3Forma y color:SolidPeso molecular:571.713CDK7-IN-31
CAS:CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.Fórmula:C27H32F5N6O2PForma y color:SolidPeso molecular:598.55(R)-Atuveciclib
CAS:Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].Fórmula:C18H18FN5O2SPureza:98%Forma y color:SolidPeso molecular:387.43TMX-3013
CAS:TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.Fórmula:C17H14BrFN6O3SForma y color:SolidPeso molecular:481.3LZ9
CAS:LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.Fórmula:C17H11F3N4O2Forma y color:SolidPeso molecular:360.29CDK1-IN-6
CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.Fórmula:C21H22N4OForma y color:SolidPeso molecular:346.43CDK2 degrader 4
CAS:CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.Fórmula:C23H26ClN3O5Forma y color:SolidPeso molecular:459.923Cimpuciclib tosylate
CAS:Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.Fórmula:C37H43FN8O4SForma y color:SolidPeso molecular:714.85CDK9-IN-11
CAS:CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].Fórmula:C20H25N3O4Pureza:98%Forma y color:SolidPeso molecular:371.43CDK1-IN-7
CAS:CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.Fórmula:C23H19ClN4O3Forma y color:SolidPeso molecular:434.88PPA-037
CAS:PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.Fórmula:C25H27N7Forma y color:SolidPeso molecular:425.53CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Fórmula:C29H28FN5OForma y color:SolidPeso molecular:481.56CDK1-IN-5
CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.Fórmula:C27H26ClN5OSForma y color:SolidPeso molecular:504.05Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Fórmula:C19H20FN5OSForma y color:SolidPeso molecular:385.458CDK9/PARP-IN-1
CAS:CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Fórmula:C38H34F2N8O3Forma y color:SolidPeso molecular:688.725YKL-1-116
CAS:YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.Fórmula:C34H38N8O3Pureza:98%Forma y color:SolidPeso molecular:606.72Protein Kinase Inhibitor 12
CAS:Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.Fórmula:C14H14N4OSPureza:98.06%Forma y color:SolidPeso molecular:286.35Anticancer agent 30
Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.Fórmula:C22H15ClFNOForma y color:SolidPeso molecular:363.81p38α inhibitor 9
CAS:p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.Fórmula:C27H24FN3O3Forma y color:SolidPeso molecular:457.496CDK2-IN-8
CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.Fórmula:C22H25N5O3Forma y color:SolidPeso molecular:407.47CDK2-IN-30
CAS:CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.Fórmula:C18H25N7O3SForma y color:SolidPeso molecular:419.50CDK7-IN-18
CAS:CDK7-IN-18 (Compound 15) is a pyrimidine-derived CDK7 inhibitor suitable for studying cancers with transcriptional dysregulation.Fórmula:C22H24F3N7OSPureza:99.28% - 99.54%Forma y color:SolidPeso molecular:491.53CDK2/4-IN-2
CAS:CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.Fórmula:C18H20F3N7O3S2Forma y color:SolidPeso molecular:503.52CDK7-IN-26
CAS:CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor with an IC50 of 7.4 nM. The compound effectively suppresses the growth of xenograft tumors derived from triple-negative breast cancer (TNBC) cell lines in vivo and has an IC50 of 0.15 μM for inhibiting MDA-MB-453 cells in vitro.Fórmula:C22H22FN6OPSPeso molecular:468.49CDK4/6-IN-3
CAS:CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.Fórmula:C25H31FN8Pureza:98%Forma y color:SolidPeso molecular:462.57CDK8-IN-14
CAS:CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].Fórmula:C18H13N3O2Forma y color:SolidPeso molecular:303.31DB18
CAS:DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].Fórmula:C24H18ClN7O3Forma y color:SolidPeso molecular:487.9DDO-6079
CAS:DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.Fórmula:C18H13ClN2O3Forma y color:SolidPeso molecular:340.76GFB-12811
CAS:GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Fórmula:C22H23F4N5OPureza:98.88%Forma y color:SolidPeso molecular:449.44LY3143921 hydrate
CAS:LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Fórmula:C16H14FN5O2Pureza:98.43%Forma y color:SolidPeso molecular:327.31Tanuxiciclib
CAS:Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Fórmula:C15H13FN6OForma y color:SolidPeso molecular:312.308GSK-3/CDK5/CDK2-IN-1
CAS:GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Fórmula:C21H22N4O2Forma y color:SolidPeso molecular:362.433Tibremciclib
CAS:Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
Fórmula:C28H32F2N8Pureza:98%Forma y color:SolidPeso molecular:518.6YK-2168
CAS:YK-2168 is a differentiated selective inhibitor of CDK9.
Fórmula:C16H18ClN5Forma y color:SolidPeso molecular:315.80Ref: TM-T200769
Producto descatalogado
